Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 19 studies | 38% ± 11% | |
lung | 16 studies | 29% ± 10% | |
intestine | 6 studies | 19% ± 2% | |
liver | 5 studies | 29% ± 5% | |
bone marrow | 4 studies | 26% ± 11% | |
heart | 4 studies | 23% ± 5% | |
uterus | 4 studies | 23% ± 5% | |
lymph node | 4 studies | 36% ± 5% | |
brain | 4 studies | 23% ± 6% | |
adipose | 4 studies | 32% ± 4% | |
kidney | 3 studies | 33% ± 9% | |
breast | 3 studies | 22% ± 0% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
thymus | 100% | 4257.53 | 653 / 653 | 100% | 20.68 | 605 / 605 |
esophagus | 100% | 2899.43 | 1444 / 1445 | 100% | 21.58 | 183 / 183 |
lung | 100% | 6469.75 | 578 / 578 | 100% | 19.47 | 1154 / 1155 |
breast | 100% | 5155.74 | 459 / 459 | 100% | 21.87 | 1114 / 1118 |
kidney | 100% | 3579.03 | 89 / 89 | 100% | 18.13 | 897 / 901 |
ovary | 100% | 3787.02 | 180 / 180 | 100% | 16.83 | 428 / 430 |
stomach | 100% | 2845.11 | 359 / 359 | 99% | 16.77 | 283 / 286 |
liver | 100% | 2399.67 | 225 / 226 | 99% | 13.22 | 402 / 406 |
bladder | 100% | 3480.33 | 21 / 21 | 98% | 15.89 | 496 / 504 |
intestine | 100% | 4342.74 | 966 / 966 | 98% | 15.15 | 518 / 527 |
uterus | 100% | 3681.54 | 170 / 170 | 98% | 15.56 | 451 / 459 |
prostate | 100% | 3584.71 | 245 / 245 | 97% | 12.98 | 489 / 502 |
pancreas | 99% | 2089.02 | 325 / 328 | 98% | 24.03 | 175 / 178 |
skin | 100% | 3751.46 | 1808 / 1809 | 97% | 19.27 | 459 / 472 |
adrenal gland | 100% | 4862.17 | 258 / 258 | 83% | 9.34 | 190 / 230 |
adipose | 100% | 5797.82 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 4851.56 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 35.43 | 29 / 29 |
spleen | 100% | 7556.95 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 5.03 | 1 / 1 |
peripheral blood | 100% | 7354.70 | 925 / 929 | 0% | 0 | 0 / 0 |
heart | 100% | 2914.88 | 857 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 98% | 19.07 | 44 / 45 |
brain | 30% | 364.61 | 801 / 2642 | 66% | 6.32 | 464 / 705 |
eye | 0% | 0 | 0 / 0 | 93% | 11.86 | 74 / 80 |
muscle | 85% | 1216.69 | 686 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0046826 | Biological process | negative regulation of protein export from nucleus |
GO_0006357 | Biological process | regulation of transcription by RNA polymerase II |
GO_0060333 | Biological process | type II interferon-mediated signaling pathway |
GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
GO_0043433 | Biological process | negative regulation of DNA-binding transcription factor activity |
GO_0034341 | Biological process | response to type II interferon |
GO_0045765 | Biological process | regulation of angiogenesis |
GO_1902044 | Biological process | regulation of Fas signaling pathway |
GO_0045185 | Biological process | maintenance of protein location |
GO_0060337 | Biological process | type I interferon-mediated signaling pathway |
GO_0000723 | Biological process | telomere maintenance |
GO_0043392 | Biological process | negative regulation of DNA binding |
GO_0010596 | Biological process | negative regulation of endothelial cell migration |
GO_1902041 | Biological process | regulation of extrinsic apoptotic signaling pathway via death domain receptors |
GO_0034340 | Biological process | response to type I interferon |
GO_0030330 | Biological process | DNA damage response, signal transduction by p53 class mediator |
GO_0030870 | Cellular component | Mre11 complex |
GO_0005654 | Cellular component | nucleoplasm |
GO_0016604 | Cellular component | nuclear body |
GO_0016605 | Cellular component | PML body |
GO_0005737 | Cellular component | cytoplasm |
GO_0000781 | Cellular component | chromosome, telomeric region |
GO_0005634 | Cellular component | nucleus |
GO_0003677 | Molecular function | DNA binding |
GO_0019904 | Molecular function | protein domain specific binding |
GO_0000981 | Molecular function | DNA-binding transcription factor activity, RNA polymerase II-specific |
GO_0070087 | Molecular function | chromo shadow domain binding |
GO_0019900 | Molecular function | kinase binding |
GO_0042802 | Molecular function | identical protein binding |
GO_0046983 | Molecular function | protein dimerization activity |
GO_0005515 | Molecular function | protein binding |
Gene name | SP100 |
Protein name | Uncharacterized protein SP100 Nuclear autoantigen Sp-100 (Nuclear dot-associated Sp100 protein) (Speckled 100 kDa) SP100 nuclear antigen SP100-HMG nuclear autoantigen |
Synonyms | |
Description | FUNCTION: Together with PML, this tumor suppressor is a major constituent of the PML bodies, a subnuclear organelle involved in a large number of physiological processes including cell growth, differentiation and apoptosis. Functions as a transcriptional coactivator of ETS1 and ETS2 according to PubMed:11909962. Under certain conditions, it may also act as a corepressor of ETS1 preventing its binding to DNA according to PubMed:15247905. Through the regulation of ETS1 it may play a role in angiogenesis, controlling endothelial cell motility and invasion. Through interaction with the MRN complex it may be involved in the regulation of telomeres lengthening. May also regulate TP53-mediated transcription and through CASP8AP2, regulate FAS-mediated apoptosis. Also plays a role in infection by viruses, including human cytomegalovirus and Epstein-Barr virus, through mechanisms that may involve chromatin and/or transcriptional regulation. . |
Accessions | H0Y4R8 C9JBL0 ENST00000432979.5 ENST00000409112.5 [P23497-3] Q53TD0 ENST00000427101.6 [P23497-6] ENST00000409897.5 [P23497-7] H7C1G8 ENST00000340126.9 [P23497-4] ENST00000431952.1 Q4ZG64 ENST00000264052.9 [P23497-1] H7C4B4 P23497 E9PHV6 ENST00000452345.1 ENST00000409824.5 ENST00000409341.5 [P23497-2] ENST00000413284.5 Q9P0W1 |